3 “Strong buy” of health stocks under $ 5 that can thrive
From 2019, the health sector is preparing for wild riding, which will be the election year. However, according to some Street professionals, 2021
looks a lot like 2009, and that may actually be good for the space. “[We] I believe that 2021 will be very similar to 2009 for the health sector. If, in fact, the political forecast markets are correct and Democrats take control of the US presidency and Senate, the rhetoric for changes in health care policy goes beyond the reality of what can be achieved, “said UBS health strategist Eric Potoker. that the adoption of the Affordable Care Act (ACA) in 2009 had a muted effect on the industry, with demand for products and services increasing due to expanded health coverage.Health stocks benefited from this between 2009 and 2015, and space surpassed The rest To this end, Potoker believes that 2021 will be played in a very similar way and therefore lists health space as a mandatory area of the market.Using the TipRanks database, we scanned the street for compelling yet accessible plays in the healthcare sector. trades for less than $ 5 a share, the platform revealed that even with the associated risk, all three have won You predominantly bullish support for alist, enough to win a consensus rating “Strong purchase”. Moreover, everyone is proud of the huge potential for promotion. Kintara Therapeutics (KTRA) Working to meet the needs of patients who are unsuccessful or resistant to current treatment regimens, Kintara Therapeutics focuses on developing advanced cancer therapies. Based on the diverse cancer-focused pipeline and a share price of $ 1.40, some Street members believe the share price reflects an attractive entry point. Egis analyst Nathan Weinstein cites the two differentiated oncological assets of the late-stage company as key components of his bull thesis. These candidates are VAL-083, a low-molecular-weight chemotherapeutic agent for the treatment of glioblastoma multiforme (GBM), a highly lethal brain cancer with 95% five-year mortality, and REM-001, phototherapy for the treatment of cutaneous metastatic breast cancer (CMBC). Looking at the first, Weinstein highlights the fact that VAL-083 affects DNA differently from the current standard of care, temozolomide (TMZ). “We believe that VAL-083 may show relative benefit, especially in non-methylated patients with MGMT. Two-thirds of GBM patients have an unmethylated MGMT promoter, “the analyst said. The MGMT repair enzyme was found to correct DNA damage caused by TMZ. However, patients with an unmethylated MGMT repair enzyme had a poor response to TMZ treatment. , which is good for KTRA because its therapy has a different mechanism of action. “In our opinion, the data from the ongoing Phase 2 trials presented to the AACR (June 2020) are encouraging in terms of overall survival (OS) and data. for progression-free survival (PFS) versus historical control, “Weinstein said. As for REM-001, it has so far been evaluated in more than 1,000 patients and thus has a” well-characterized safety profile, “according to Weinstein. in previous CMBC studies, the asset has demonstrated stable efficacy, including an 80% complete response to assessable lesions, prompting Weinstein to comment: “We believe that Kintara’s market valuation has been as it has little value attributable to the company, although it has two ready-made oncology assets for phase 3 with sufficient funding to achieve many stages forward. “To this end, Weinstein values KTRA a Buy along with a price tag of $ 6. This goal expresses his confidence in KTRA’s ability to climb 341% next year. (To view Weinstein’s recording, click here) Do other analysts agree? They are. In the last three months, only buy ratings have been issued, namely 3. Therefore, the word on the street is that KTRA is a strong purchase. Given the target for an average price of $ 4.33, stocks could jump 218% from current levels. (See KTRA stock analysis for TipRanks) DiaMedica Therapeutics (DMAC) Using its state-of-the-art technology, DiaMedica Therapeutics is developing new recombinant proteins for the treatment of kidney and neurological diseases. With a price of $ 4.20 per share and potential catalysts, it’s no wonder this stock is on Wall Street radar. Introducing Craig-Hallum, analyst Alexander Novak sees a number of catalysts for value creation, noting that the company seems “chronically undervalued.” Looking ahead to Q4, the DMAC will meet with the FDA for DM199 in acute ischemic stroke (AIS), where the breakthrough designation, Special Protocol Assessment (SPA), Phase 3 test design and Phase 3 study green light will be discussed. DM199, the leading candidate for DMAC, is a recombinant form of the KLK1 protein (an endogenous serine protease produced in the kidneys, pancreas and salivary glands). According to Nowak, this Phase 3 study is the next major potential catalyst and could lead to strategic partnership talks. He added: “We also believe that a SPA that confirms the exclusion of mechanical thrombectomy and occlusion of large vessels and mRS / NIHSS Excellent endpoints is a big gain (actually means to repeat a Phase 2 study to treat the population).” While the meeting will take place later than Novak thought (he originally expected a meeting in August), the delay is due to the hiring of an external advisory group to help communicate the FDA, a “valid and reasonable reason for withdrawal.” in his opinion. this, DM199 was evaluated in chronic kidney disease (CKD). Trial phase 2 recording was temporarily paused in Q2, but recording was improving. It should be noted that the delays are mainly related to patients who were nervous from entering the clinic for initial setup during the COVID crisis. With this in mind, the analyst expects the reporting to come in the first quarter of 2021. To summarize, Novak said: “We still consider the CKD phase 2 trial as the more significant, immediate opportunity to create value, given the large market and recent industry successes (RETA). But we are also more bullish than most investors in stroke, as the only drug used is more than two decades old, there are no serious competitors and approval (which can only be done in a few hundred patients) can lead to very rapid absorption within at 1-2 years. Everything DMAC is doing about it has persuaded Nowak to repeat its Buy rating. Along with the call, he applied a price tag of $ 15, which implies a 265% increase potential. (To watch the Nowak record, click here) Overall, DMAC shares unanimously gained thumbs from analysts’ consensus, with 3 recent buy reviews adding a strong buy rating. At $ 14.33, the average price target assumes a 248% potential to increase from current levels. (See DMAC stock analysis for TipRanks) OPKO Health (OPK) Through its unique products, comprehensive diagnostic laboratories and robust research and development pipeline, OPKO Health wants to improve patients’ lives. Shares of OPKO rose 162% this year, but at $ 3.86 in number, some analysts believe this stock is still undervalued. Following the announcement that OPK has launched Rayaldee’s Phase 2 REsCue study to treat a drug up to moderate COVID-19, 5-star analyst Edward Tenthoff, of Piper Sandler, said he had high hopes for the company. Rayaldee is currently approved for secondary hyperparathyroidism (SHPT) in stage 3-4 Chronic Kidney Disease (CRD) and is progressing in a phase 2 study in dialysis patients. According to Tenthoff, many patients in the COVID study will have stage 3 -4 CKD, “where Rayaldee has shown clinical benefit.” reflects another positive, revenue from services of $ 251 million in the second quarter of 2020 exceeded expectations as a result of 2.2 million SARS-CoV-2 PCRs and antibody tests performed at BioReference Labs during the quarter. In addition to the good news, OPK is targeting 45,000-55,000 tests per day in Q3 2020 and revenue from services of $ 325-350 million in the quarter. It should be noted that this involves the basic diagnostic business, which is starting to go back. To that end, Tenthoff estimates that service revenue could climb 53 percent to $ 1.1 billion this year. Tenthoff is also looking forward to somatrogon, the company’s treatment for pediatric growth hormone (GHD) deficiency, regulations. Its partner, Pfizer, plans to introduce the BLA this fall, with US approval and launch possible in 2H21. An open European study is expected to end this quarter and will allow for EMA applications in 2021. In addition, the main phase 3 Japanese data in pediatric patients with GHD may support regulatory filing in the country in 1H21. In a phase 3 test in which he reached the main endpoint with speed altitude, Tenthoff saw the approval as likely. In keeping with his optimistic approach, Tenthoff stays with the bulls. To this end, it maintains an overweight rating (ie Buy) and a price price of $ 10 per share. Investors can gain a profit of 159% if this goal is met in the next twelve months. (To watch Tenthoff’s recording, click here) In general, other analysts echo Tenthoff’s mood. 4 Purchases and no retentions or sales are added to the strong purchase rating. With an average price of $ 8, the potential for growth is 107%. (See OPKO stock analysis for TipRanks.) To find good ideas for health stocks trading at attractive ratings, visit TipRanks’ Best Buy Stocks, a newly created tool that brings together all insights into TipRanks ownership. Disclaimer: The views expressed in this article are those of the analysts submitted. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.